登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Claudin-18.2 >CL2-H82E3

Biotinylated Human / Cynomolgus Claudin-18.2 Protein, His,Avitag™ (Detergent)

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

Claudin-18.2,CLDN18,Claudin-18

表达区间及表达系统(Source)

Biotinylated Human / Cynomolgus Claudin-18.2, His,Avitag (CL2-H82E3) is expressed from Baculovirus-Insect cells. It contains AA Met 1 - Ala 200 (Accession # P56856-2 ). In the region AA Met 1 - Ala 200, the AA sequence of Human and Cynomolgus Claudin-18.2 are homologus.

Predicted N-terminus: Met

Request for sequence

蛋白结构(Molecular Characterization)

Claudin-18.2 Structure

This protein carries an Avi tag at the N-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 24.8 kDa.
It is produced as active membrane protein with full ECD epitopes, and contains both the ECL1 and ECL2.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>60% as determined by SDS-PAGE.

制剂(Formulation)

This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.

Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 3 months under sterile conditions.
**The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow this link for product information.
 

活性(Bioactivity)-ELISA

Claudin-18.2 ELISA

Immobilized Biotinylated Human / Cynomolgus Claudin-18.2, His,Avitag (Cat. No. CL2-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

Claudin-18.2 SPR

Biotinylated Human / Cynomolgus Claudin-18.2, His,Avitag (Cat. No. CL2-H82E3) captured on Biotin CAP-Series S Sensor Chip can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with an affinity constant of 4.74 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

背景(Background)

Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Claudin-18.2靶点信息
英文全称:Claudin-18 splice variant 2
中文全称:密蛋白-18剪接变体2
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:62详情
最高研发阶段:申请上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定